Vasodilator potencies of GTN, SNAP, and DEA/NO as evaluated by cumulative application to ring segments of porcine coronary arteries precontracted with 50 μm PGF2α
| Drug | Preincubationwith | pD2 | n |
|---|---|---|---|
| GTN | Vehicle | 6.32 ± 0.10 | 7 |
| GTN | 5.16 ± 0.122-a | 7 | |
| SNAP | 5.59 ± 0.142-a | 6 | |
| DEA/NO | 5.43 ± 0.122-a | 5 | |
| SPER/NO | 5.54 ± 0.102-a | 5 | |
| SNAP | Vehicle | 7.55 ± 0.06 | 9 |
| GTN | 7.35 ± 0.16 | 6 | |
| DEA/NO | Vehicle | 7.27 ± 0.09 | 8 |
In some experiments, preincubation with GTN (100 μm), SNAP (100 μm), DEA/NO (four times 100 μmevery 8 min), or SPER/NO (200 μm) preceded cumulative applications. Given are mean pD2- values (in −logm) and standard error values for n individual experiments.
↵2-a Significant difference compared with vehicle conditions.